Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Angiocrine Bioscience Licenses New Stem Cell TechnologyAdvances in Cell Based Assays, 11th & 12th November 2014, London UK
By: SMi Group “This technology nicely complements our efforts in applying our VeraVec™ platform to the expansion of umbilical cord blood stem cells, another approach toward making stem cell transplant safer and more broadly available to patients in need, ” said Geoff Davis, Angiocrine’s CEO.* Source http://www.digitaljournal.com/ Hear more from Angiocrine Bioscience at Advances in Cell Based Assays this autumn as Director of Research, Dr Daniel Nolan, provides further insights into the VeraVec™ platform. The talk will discuss recent works demonstrating how the chemoresistant niche within cancer involves the vasculature, a look into how the vascular stem cell niche is capable of expanding stem cells in vitro while maintaining potency and engraftability, plus VeraVec™ amenability to 3D and co-culture assays for screening purposes. Other Speakers Include: - Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK - Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D - Dr Lesley Jenkinson, Scientist 1, MedImmune - Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB - Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh - Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma - Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono - Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis For further details and to secure a place at Advances in Cell Based Assays, visit www.cellbasedassay.co.uk 7th annual conference: Advances in Cell Based Assays 11th & 12th November 2014 Marriott Regents Park Hotel, London UK www.cellbasedassay.co.uk ---end--- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|